BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9613779)

  • 21. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission.
    Blaise D; Gaspard MH; Stoppa AM; Michel G; Gastaut JA; Lepeu G; Tubiana N; Blanc AP; Rossi JF; Novakovitch G
    Bone Marrow Transplant; 1990 Jan; 5(1):7-12. PubMed ID: 2404531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
    Browne EK; Moore C; Sykes A; Lu Z; Jeha S; Mandrell BN
    J Pediatr Oncol Nurs; 2018; 35(2):103-109. PubMed ID: 29161979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PEG-asparaginase.
    Fu CH; Sakamoto KM
    Expert Opin Pharmacother; 2007 Aug; 8(12):1977-84. PubMed ID: 17696798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
    Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
    Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children.
    Bureo E; Ortega JJ; Muñoz A; Cubells J; Madero L; Verdaguer A; Baro J; Olivé T; Maldonado MS; Pardo N
    Bone Marrow Transplant; 1995 Mar; 15(3):353-9. PubMed ID: 7599558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
    Christ TN; Stock W; Knoebel RW
    J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegaspargase: a review of clinical studies.
    Graham ML
    Adv Drug Deliv Rev; 2003 Sep; 55(10):1293-302. PubMed ID: 14499708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis.
    Göpel W; Schnetzke U; Hochhaus A; Scholl S
    Ann Hematol; 2016 Oct; 95(11):1899-901. PubMed ID: 27488287
    [No Abstract]   [Full Text] [Related]  

  • 30. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
    Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
    Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.
    Armstrong JK; Hempel G; Koling S; Chan LS; Fisher T; Meiselman HJ; Garratty G
    Cancer; 2007 Jul; 110(1):103-11. PubMed ID: 17516438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time Course and Management of Protracted Anaphylaxis Due to PEG-Asparaginase.
    Fertal SA; Bradeen HA; Friesen E; Heath JL
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e385-e387. PubMed ID: 32815880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
    Albertsen BK; Harila-Saari A; Jahnukainen K; Lähteenmäki P; Riikonen P; Möttönen M; Lausen B
    Leuk Lymphoma; 2019 Jun; 60(6):1469-1475. PubMed ID: 30632847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma.
    Agrawal NR; Bukowski RM; Rybicki LA; Kurtzberg J; Cohen LJ; Hussein MA
    Cancer; 2003 Jul; 98(1):94-9. PubMed ID: 12833461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)].
    Badell I; Ortega JJ; Muñoz A; Bureo E; Madero L; Olivé T; Cubells J; Maldonado MS; Baro J; Díaz MA
    Sangre (Barc); 1996 Apr; 41(2):101-8. PubMed ID: 9045349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.
    Narta UK; Kanwar SS; Azmi W
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):208-21. PubMed ID: 17011787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical experiences with polyethylene glycol-bound E. coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia].
    Jürgens H; Schwamborn D; Körholz D; Wahn V; Göbel U
    Klin Padiatr; 1988; 200(3):184-9. PubMed ID: 3210651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
    Vieira Pinheiro JP; Lanversa C; Würthwein G; Beier R; Casimiro da Palma J; von Stackelberg A; Boos J
    Leuk Lymphoma; 2002 Oct; 43(10):1911-20. PubMed ID: 12481884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.
    Pound CM; Keene DL; Udjus K; Humphreys P; Johnston DL
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):183-6. PubMed ID: 17356399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second allogeneic bone marrow transplantation after myeloablative conditioning analysis of 43 cases from single institution.
    Al-Qurashi F; Ayas M; Al Sharif F; Ibrahim E; Sahovic E; Al Mahr M; Chaudhri N; Al Mohareb F; Al Zahrani H; Al Jefri A; Al Omar H; Al Shanqeeti A; Seth P; Aslam M; El Solh H; Aljurf M
    Hematology; 2004 Apr; 9(2):123-9. PubMed ID: 15203867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.